Immix Biopharma has closed its previously announced underwritten registered offering of 11,363,637 shares of common stock at a public offering price of $11.00 per share, raising gross proceeds of $125 million. Net proceeds to the company, after deducting underwriting discounts, commissions and other offering expenses, were approximately $117.1 million. Immix intends to use the net proceeds to fund NXC-201 development, working capital and general corporate purposes. J.P. Morgan acted as the sole book-running manager for the offering, which included participation from leading U.S. biotechnology institutional investors and mutual funds. The shares were sold under a shelf registration statement on Form S-3 filed with the U.S. Securities and Exchange Commission on January 9, 2026, and declared effective on January 22, 2026.
Immix Biopharma IncImmix Biopharma closed a $125M underwritten offering, raising ~$117.1M net to fund NXC-201 development and working capital.
JPMorgan Chase & Co
